S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Digirad Co. stock logo
DRAD
Digirad
$0.88
-1.1%
$3.58
$1.99
$8.84
$4.21M0.18485,592 shs16,453 shs
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
$0.26
-29.6%
$0.91
$0.26
$2.79
$2.89M0.98172,436 shs413,604 shs
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
$0.00
$0.00
$0.00
$0.11
$3K0.083,544 shs4,761 shs
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Digirad Co. stock logo
DRAD
Digirad
0.00%-2.72%-1.65%-6.78%+10.43%
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
0.00%-1.33%-63.00%-71.54%-80.00%
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
0.00%+50.00%+50.00%+50.00%-99.39%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Digirad Co. stock logo
DRAD
Digirad
N/AN/AN/AN/AN/AN/AN/AN/A
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Digirad Co. stock logo
DRAD
Digirad
N/AN/AN/AN/A
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/AN/AN/AN/A
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Digirad Co. stock logo
DRAD
Digirad
$114.18M0.04$1.28 per share0.69$10.30 per share0.09
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/AN/AN/AN/A$0.67 per shareN/A
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
$6.43M0.00N/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Digirad Co. stock logo
DRAD
Digirad
-$4.63M-$0.35N/AN/A-5.32%-3.75%-0.85%N/A
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
-$10.06M-$1.93N/AN/AN/A-197.36%-144.22%5/20/2024 (Estimated)
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
-$22.03MN/A0.00N/AN/AN/AN/A4/15/2024 (Estimated)

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Digirad Co. stock logo
DRAD
Digirad
$2.20248.62%N/AN/A N/A
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/AN/AN/AN/AN/A
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Digirad Co. stock logo
DRAD
Digirad
0.88
1.27
0.91
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/A
6.26
3.36
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Digirad Co. stock logo
DRAD
Digirad
11.38%
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
1.19%
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
N/A

Insider Ownership

CompanyInsider Ownership
Digirad Co. stock logo
DRAD
Digirad
12.49%
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
4.80%
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
5.73%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Digirad Co. stock logo
DRAD
Digirad
6184.76 millionN/ANot Optionable
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
2111.04 million10.51 millionNot Optionable
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
4710.72 million10.11 millionNot Optionable

NDRA, DRAD, and VIVE Headlines

SourceHeadline
InMode Responds To BTL Petition for Inter Partes Review Of Patent InMode Is Asserting Against BTLInMode Responds To BTL Petition for Inter Partes Review Of Patent InMode Is Asserting Against BTL
finance.yahoo.com - April 15 at 7:58 AM
Viveve Medical Stock (OTC:VIVE), Analyst Ratings, Price Targets, PredictionsViveve Medical Stock (OTC:VIVE), Analyst Ratings, Price Targets, Predictions
benzinga.com - February 23 at 10:31 AM
The Best Medical Billing Services of 2024The Best Medical Billing Services of 2024
business.com - January 19 at 10:31 PM
VIVE Viveve Medical, Inc.VIVE Viveve Medical, Inc.
seekingalpha.com - July 29 at 9:53 AM
InMode Expands Womens Health and Wellness Market Footprint through Acquisition of Viveve PatentsInMode Expands Women's Health and Wellness Market Footprint through Acquisition of Viveve Patents
finance.yahoo.com - July 25 at 9:01 AM
VIVE - Viveve Medical, Inc.VIVE - Viveve Medical, Inc.
uk.finance.yahoo.com - June 14 at 7:59 PM
Viveve Medical, Inc. (VIVE)Viveve Medical, Inc. (VIVE)
finance.yahoo.com - February 24 at 8:19 AM
Viveve Medical announces study result from PURSUIT clinical trial to treat female stress urinary incontinenceViveve Medical announces study result from PURSUIT clinical trial to treat female stress urinary incontinence
pharmabiz.com - January 20 at 9:26 AM
Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesdays Mid-Day SessionWhy Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
msn.com - January 17 at 3:40 PM
Viveve Medical, Inc.: Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary IncontinenceViveve Medical, Inc.: Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary Incontinence
finanznachrichten.de - January 17 at 10:39 AM
Viveve crashes ~60% as company decides to delist, explore sale after trial failsViveve crashes ~60% as company decides to delist, explore sale after trial fails
seekingalpha.com - January 17 at 10:39 AM
Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary IncontinenceViveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary Incontinence
finance.yahoo.com - January 17 at 10:39 AM
Viveve Medical Seeks Strategic Alternatives After Failed Stress Urinary Incontinence TrialViveve Medical Seeks Strategic Alternatives After Failed Stress Urinary Incontinence Trial
finance.yahoo.com - January 17 at 10:39 AM
Why Is Viveve Medical (VIVE) Stock Down 69% Today?Why Is Viveve Medical (VIVE) Stock Down 69% Today?
investorplace.com - January 17 at 10:03 AM
Viveve Medical, Inc. (NASDAQ:VIVE) Q3 2022 Earnings Call TranscriptViveve Medical, Inc. (NASDAQ:VIVE) Q3 2022 Earnings Call Transcript
insidermonkey.com - December 29 at 9:56 AM
Viveve Announces Completion of Pivotal US PURSUIT Trial for Female Stress Urinary Incontinence with Final 12-month Follow-up Visits ConcludedViveve Announces Completion of Pivotal US PURSUIT Trial for Female Stress Urinary Incontinence with Final 12-month Follow-up Visits Concluded
finance.yahoo.com - December 15 at 10:21 AM
Viveve gets US patent for treating female stress urinary incontinenceViveve gets US patent for treating female stress urinary incontinence
pharmabiz.com - December 3 at 7:46 AM
Viveve Medical, Inc.: Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary IncontinenceViveve Medical, Inc.: Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence
finanznachrichten.de - December 1 at 12:46 PM
Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary IncontinenceViveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence
finance.yahoo.com - December 1 at 12:46 PM
Viveve Medical Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagViveve Medical Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
finance.yahoo.com - November 13 at 7:01 PM
InvestorNewsBreaks — Viveve Medical Inc. (NASDAQ: VIVE) Releases Q3 2022 Financial Report, Corporate UpdateInvestorNewsBreaks — Viveve Medical Inc. (NASDAQ: VIVE) Releases Q3 2022 Financial Report, Corporate Update
markets.buffalonews.com - November 12 at 7:52 AM
Viveve Medical, Inc.: Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateViveve Medical, Inc.: Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate Update
finanznachrichten.de - November 10 at 4:16 PM
Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateViveve Reports Third Quarter 2022 Financial Results and Provides Corporate Update
finance.yahoo.com - November 10 at 4:16 PM
Viveve to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10, 2022Viveve to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10, 2022
finance.yahoo.com - October 27 at 6:56 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Digirad logo

Digirad

NASDAQ:DRAD
Digirad Corporation provides healthcare solutions in the United States and internationally. It operates through five segments: Diagnostic Services, Diagnostic Imaging, Mobile Healthcare, Building and Construction, and Real Estate and Investments. The company offers imaging and monitoring services to healthcare providers; and contract diagnostic imaging, including computerized tomography (CT), magnetic resonance imaging, positron emission tomography (PET), PET/CT, and nuclear medicine and healthcare services to hospitals, integrated delivery networks, and federal institutions on a long-term contract basis, as well as provisional services to institutions that are in transition. It also develops, sells, and maintains solid-state gamma cameras, such as nuclear cardiac imaging systems and general purpose nuclear imaging systems to physician offices and hospitals; and offers camera maintenance contract services. In addition, it manufactures modular housing units, structural wall panels, permanent wood foundation systems, and other engineered wood products; supplies general contractors with building materials; and manages real estate assets and investments. Digirad Corporation was founded in 1985 and is headquartered in Suwanee, Georgia.
ENDRA Life Sciences logo

ENDRA Life Sciences

NASDAQ:NDRA
ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Viveve Medical logo

Viveve Medical

NASDAQ:VIVE
Viveve Medical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company offers Viveve System comprises of the radiofrequency generator, reusable handpiece, and treatment tip, as well as cryogen canister and other consumable components. It markets its products through sales employees and distributors in the United States, Canada, the Asia Pacific, Europe, the Middle East, Latin America, and internationally. Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.